Proton Pump Inhibitors (Antacids): Possible Risk of Clostridium Difficile-Associated Diarrhea
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 02/16/12 -- Health Canada is informing Canadians of a possible association between the use of prescription stomach antacids known as proton pump inhibitors (PPIs) and an increased risk of Clostridium difficile-associated diarrhea (CDAD).
Clostridium difficile, commonly called C. difficile, is a bacterium that can cause diarrhea and may lead to more serious intestinal conditions. Healthy people are not usually vulnerable to C. difficile. Factors known to increase the risk of infection include advanced age, severe underlying illness, hospitalization, or antibiotic use.
PPIs reduce stomach acid and are widely used to treat conditions such as acid reflux, and stomach and small intestine ulcers. See below for a list of () available in Canada.
There have been a number of studies suggesting a possible link between PPIs and an increased risk of CDAD, particularly in vulnerable patients. Health Canada has been assessing this data on an ongoing basis.
The studies acknowledge important limitations with regards to study design and the impossibility of establishing a definite cause-and-effect relationship between PPIs and an increased risk of CDAD, as there are a number of other factors that may play a role.
While a definite association between PPI use and CDAD has not been confirmed, the possibility has not been ruled out at this time. The potential for an increased risk of C.difficile infection is identified in the Canadian labelling for PPI drugs. Health Canada will continue to monitor this issue, evaluate the scientific evidence as it emerges and take appropriate action as necessary.
Patients taking a PPI who develop a diarrhea that does not improve should speak to a healthcare professional immediately as this may be CDAD. Symptoms include severe watery or bloody diarrhea (at least three bowel movements per day for two or more days); fever; loss of appetite; nausea; and abdominal pain or tenderness.
Patients taking a PPI should talk with their doctor or pharmacist if they have questions or concerns about their antacid treatment.
Health professionals are reminded that PPIs should be prescribed at the lowest dose and shortest duration of therapy appropriate to the condition being treated. A diagnosis of CDAD should be considered for any patient who has risk factors for CDAD and who has persistent or severe diarrhea.
Drug labels, also known as "Product Monographs," contain important prescribing and safety information for health professionals and patients, and are available by search of Health Canada's ().
How to report side effects to health products
To report suspected adverse reaction (side effect) to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a () and send to us using one of these methods:
- Fax: 1-866-678-6789
- Internet:
- Mail ( ):
PPI drugs currently marketed in Canada
The following proton pump inhibitors are available in Canada:
PPIs are also available in combination with other drugs, for example: Vimovo (contains esomeprazole).
Egalement disponible en francais
Contacts:
Media Inquiries:
Health Canada
613-957-2983
Public Inquiries:
613-957-2991
1-866-225-0709
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.02.2012 - 10:25 Uhr
Sprache: Deutsch
News-ID 1083991
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Anmerkungen:
Diese Pressemitteilung wurde bisher 71 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Proton Pump Inhibitors (Antacids): Possible Risk of Clostridium Difficile-Associated Diarrhea
"
steht unter der journalistisch-redaktionellen Verantwortung von
Health Canada (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
